<DOC>
	<DOCNO>NCT02798406</DOCNO>
	<brief_summary>Glioblastoma ( GBM ) gliosarcoma ( GS ) common aggressive form malignant brain tumor adult resistant conventional therapy . The purpose Phase II study evaluate well recurrent glioblastoma gliosarcoma tumor respond one injection DNX-2401 , genetically modify oncolytic adenovirus , deliver directly tumor follow administration intravenous pembrolizumab ( immune checkpoint inhibitor ) give every 3 week 2 year disease progression . Funding Source-FDA OOPD</brief_summary>
	<brief_title>Combination Adenovirus + Pembrolizumab Trigger Immune Virus Effects</brief_title>
	<detailed_description>In initial phase study , 12 evaluable subject enrol 3 dose cohort determine best dose DNX-2401 , follow : - Cohort 1 : Single dose DNX-2401 ( 5e8 vp ) deliver intratumorally cannula , follow intravenous pembrolizumab every 3 week ( Q3W ) - Cohort 2 : Single dose DNX-2401 ( 5e9 vp ) deliver intratumorally cannula , follow intravenous pembrolizumab every 3 week ( Q3W ) - Cohort 3 : Single dose DNX-2401 ( 5e10 vp ) deliver intratumorally cannula , follow intravenous pembrolizumab every 3 week ( Q3W ) Following initial phase , 36 additional subject diagnose recurrent glioblastoma gliosarcoma enrol receive single DNX-2401 determine initial phase administer intratumorally follow intravenous pembrolizumab every 3 week . All subject return clinic study follow-up visit regular interval safety monitoring , MRI scan assessment , 2 year disease progression . All subject follow closely safety survival .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Neoplasms Histologic Type</mesh_term>
	<mesh_term>Neoplasms , Nerve Tissue</mesh_term>
	<mesh_term>Neoplasms , Neuroepithelial</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>A single glioblastoma gliosarcoma tumor histopathological confirmation first present second recurrence glioblastoma gliosarcoma time consent Gross total partial tumor resection possible plan A single measurable tumor least 10.0 mm long diameter ( LDi ) X 10.0 mm shortest diameter ( SDi ) tumor exceed 40.0 mm LDi SDi Tumor recurrence progression document previously fail surgical resection , chemotherapy and/or radiation Karnofsky performance status ≥ 70 % Prior antitumor therapy must complete within time period specify protocol prior DNX2401 injection Multiple ( ≥ 2 ) separate enhance tumor Tumor location side brain and/or involvement would present risk inject DNX2401 ventricle brain Tumor location brain stem Requires treatment highdose systemic corticosteroid within 2 week start intravenous pembrolizumab infusion Uncontrolled bloodsugar level define HbA1c &gt; 7 % 2 separate measurement Previous treatment antiPD1 PDL1 agent include pembrolizumab ( KEYTRUDA ) checkpoint inhibitor ( ) ( e.g. , ipilimumab , nivolumab , etc . ) Evidence active , noninfectious pneumonitis and/or history interstitial lung disease Prior gene transfer therapy prior therapy cytolytic virus type Brain tumor measurable MRI person unable MRIs Pregnant nursing female Note : Other protocoldefined inclusion exclusion criterion may apply outlined relevant protocol version</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>brain</keyword>
	<keyword>Central Nervous System ( CNS ) disease</keyword>
	<keyword>Central Nervous System ( CNS ) neoplasm</keyword>
	<keyword>CNS</keyword>
	<keyword>conditionally replicative adenovirus</keyword>
	<keyword>DNX-2401</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>KEYTRUDA</keyword>
	<keyword>MK-3475</keyword>
	<keyword>SCH 900475</keyword>
	<keyword>lambrolizumab</keyword>
	<keyword>neoplasm , germ cell embryonal</keyword>
	<keyword>neoplasm , granular epithelial</keyword>
	<keyword>Alcyone</keyword>
	<keyword>Alcyone Lifesciences</keyword>
	<keyword>AMC</keyword>
	<keyword>cannula</keyword>
	<keyword>MEMS cannula</keyword>
	<keyword>DNX-2401 + pembrolizumab</keyword>
	<keyword>Delta-24</keyword>
	<keyword>Delta-24-RGD</keyword>
	<keyword>Checkpoint inhibitor</keyword>
	<keyword>anti-PD1/PD-L1</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>KEYNOTE-192</keyword>
</DOC>